A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib (CMR-CML)

Inclusion Criteria:

• Chronic Myeloid Leukemia in the Chronic Phase
• 20 years old over
• ECOG performance status (PS) score 0-2
• Patients for major molecular response (MMR) with no CMR
• Adequate organ function (hepatic, renal and lung)
• Signed written informed consent

Exclusion Criteria:

• A case with the double cancer of the activity
• Women who are pregnant or breastfeeding
• The case of Pleural effusion clearly

• Patients with complications or a history of severe or uncontrolled cardiovascular failure following

  • have a Myocardial infarction within 6 months
  • have an Angina within 3 months
  • have a Congestive heart failure within 3 months
  • have a suspected congenital QT syndrome
  • have a QTc interval of more than 450msec at baseline
• A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy
• Prior treatment with dasatinib
• Subjects with T315I, F317L and V299L BCR-ABL point mutations